Trials that use: ANOVA
New to this method? Read the tutorial →
7 results
- ACCELERATEComplete statistical analysis of ACCELERATE (NCT01687998), a randomized phase 3 study of evacetrapib versus placebo in high-risk vascular disease, including trial design, composite cardiovascular endpoints, Cox modeling, ANOVA, confidence intervals, p-values, and…
- Ad26.COV2.SIndependent statistical analysis of the phase 3 Ad26.COV2.S trial in healthy adults for COVID-19 prevention, including randomized design, influenza and SARS-CoV-2 immunogenicity endpoints, ANOVA, geometric mean ratios, non-inferiority, confidence intervals, and safety.
- COMET-PEAKIndependent statistical analysis of COMET-PEAK, the randomized phase 2 trial evaluating second-generation sotrovimab material in non-hospitalized participants with mild to moderate COVID-19, including viral-load, pharmacokinetic, ANCOVA, ANOVA, safety, and statistical interpretation.
- DISCOVERIndependent statistical analysis of the DISCOVER phase 3 trial evaluating F/TAF versus F/TDF for HIV-1 pre-exposure prophylaxis, including non-inferiority testing, rate-ratio analysis, BMD, renal biomarkers, and statistical methodology.
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…